[
  {
    "ts": "2026-01-08T07:12:50+00:00",
    "headline": "Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL",
    "summary": "Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for newly diagnosed high-risk diffuse large B-cell lymphoma patients without new safety issues. This strengthens the case for tafasitamab as a potential first-line option in a major lymphoma indication, pending planned regulatory filings in 2026. We’ll now examine how the successful frontMIND Phase...",
    "url": "https://finance.yahoo.com/news/incyte-incy-11-9-phase-071250491.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "98faaf0d-5f08-359e-9f7d-b45c4bbf2b05",
      "content": {
        "id": "98faaf0d-5f08-359e-9f7d-b45c4bbf2b05",
        "contentType": "STORY",
        "title": "Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL",
        "description": "",
        "summary": "Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for newly diagnosed high-risk diffuse large B-cell lymphoma patients without new safety issues. This strengthens the case for tafasitamab as a potential first-line option in a major lymphoma indication, pending planned regulatory filings in 2026. We’ll now examine how the successful frontMIND Phase...",
        "pubDate": "2026-01-08T07:12:50Z",
        "displayTime": "2026-01-08T07:12:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-11-9-phase-071250491.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-11-9-phase-071250491.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]